Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Roswell Park Comprehensive Cancer Center

Sites in Buffalo, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
528
Shown on this page
12
Current sort
Recently updated
Campus scope
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Roswell Park Comprehensive Cancer Center, Buffalo, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 397–408 of 528 matching trials with a site at Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951
Site status not listed — check the official record
View directory record Official record
Conditions
Thoracic Tumors, Non-small Cell Lung Cancer
Interventions
Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Not yet recruiting No phase listed Observational

The Canopy Cancer Collective Clinical Registry Protocol

NCT07605702
Site status not listed — check the official record
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Pancreatic Cancer, Colorectal Cancer, GI Cancers, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC, GI Cancer
Interventions
Not listed
Lead sponsor
Canopy Cancer Collective, LLC
Network
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
10
States / cities
San Diego, California • Tampa, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT05682443
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects

NCT07107139
Status at this site: Recruiting
View directory record Official record
Conditions
Smokeless Tobacco
Interventions
Copenhagen group, Snus group
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

NCT03151629
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care
Other
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Other
Eligibility
21 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
48
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing

NCT07142668
Status at this site: Recruiting
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Harm Reduction Tax - Normal Nicotine Cigarettes Available, Harm Reduction Tax - Normal Nicotine Cigarettes Not Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available, Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available, Nicotine Content Tax - Normal Nicotine Cigarettes Available, Nicotine Content Tax - Normal Nicotine Cigarettes Not Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Available, Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
Status at this site: Recruiting
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04067830
Status at this site: Recruiting
View directory record Official record
Conditions
Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Best Practice, Laparoscopic Surgery, Quality-of-Life Assessment, Questionnaire Administration, Respiratory Muscle Training Device, Video-Assisted Thoracic Surgery
Other · Procedure · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT01790152
Status at this site: Suspended
View directory record Official record
Conditions
Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Interventions
Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

NCT02334865
Site status not listed — check the official record
View directory record Official record
Conditions
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Interventions
Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 5:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 5:35 AM EDT

About this Roswell Park Comprehensive Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Roswell Park Comprehensive Cancer Center in Buffalo, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.